Tag: nuclear medicine radioisotopes market share analysis

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Nuclear Medicine Radioisotopes Market Poised To Hit $12.75 Billion By 2030 With A 7.4% CAGR

The nuclear medicine radioisotopes market size has demonstrated robust expansion in recent years. This market is expected to expand from $8.85 billion in 2025 to $9.58 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.2%. The past growth can be ascribed to several factors, including the extensive application of technetium-99m in diagnostic imaging, the increasing uptake of nuclear cardiology procedures, the rising incidence of cancer and thyroid disorders, the growth of hospital-based nuclear medicine departments, and the early favorable outcomes of radioisotope-based therapies.

The nuclear medicine radioisotopes market size is anticipated to experience robust expansion over the coming years. This market is projected to reach $12.75 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.4%. The projected growth during this period is primarily driven by several factors, including the increasing need for personalized cancer treatments, a surge in the application of lutetium-177 and actinium-225 therapies, the expanding infrastructure for PET imaging, rising investments in cyclotron and reactor facilities, and the increasing integration of nuclear medicine in developing countries. Key trends expected within this forecast timeframe encompass the increasing implementation of theranostics in cancer care, a growing demand for PET and SPECT imaging techniques, enhanced utilization of targeted alpha and beta emitters, the broadening application of nuclear medicine in cardiology and neurology, and a reinforced emphasis on localized radioisotope manufacturing.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=56236388&type=smp&name=Nuclear%20Medicine%20Radioisotopes%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Nuclear Medicine Radioisotopes Market Development Factors: What’s Supporting Demand?

The increasing incidence of cardiovascular ailments is projected to drive the expansion of the nuclear medicine radioisotope market in the foreseeable future. These conditions encompass various illnesses impacting the heart and blood vessel system. The surge in cardiovascular disease cases is linked to inactive lifestyles, unhealthy eating patterns, growing obesity prevalence, and an aging demographic. Nuclear medicine radioisotopes play a crucial role in the diagnosis, assessment, and management of cardiovascular diseases, offering comprehensive data on cardiac function, blood flow, and tissue health, which is vital for precise diagnosis and successful treatment strategies. As an illustration, the American Heart Association, a US-based non-profit organization, reported in January 2024 that the age-adjusted mortality rate from cardiovascular disease escalated to 233.3 per 100,000 in 2024, representing a 4.0% rise from 224.4 per 100,000 in 2023. Consequently, the growing number of cardiovascular disease instances is fueling the expansion of the nuclear medicine radioisotope market.

Nuclear Medicine Radioisotopes Market Segmentation And Category Overview

The nuclear medicine radioisotopes market covered in this report is segmented –

1) By Type: Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Iodine (I-123), Fluorine-18, Rubidium-82 (Rb-82), Iodine-131 (I-131), Lutetium-177 (Lu-177), Radium-223 (Ra-223) And Alpharadin, Other Types

2) By Application: Oncology, Cardiology, Thyroid, Neurology, Other Applications

3) By End-User: Hospitals, Diagnostic Centers, Specialty Clinics, Education And Research Institutes, Other End-Users

Subsegments:

1) By Technetium-99m (Tc-99m): Sodium Pertechnetate Tc-99m, Tc-99m MDP (Methylene Diphosphonate), Tc-99m HMPAO (Hexamethylpropyleneamine oxime)

2) By Thallium-201 (Tl-201): Thallous Chloride Tl-201, Thallium-201 for Cardiac Imaging

3) By Iodine-123 (I-123): Iodine-123 Sodium Iodide, Iodine-123 Ioflupane (DaTscan)

4) By Fluorine-18: FDG (Fluorodeoxyglucose) F-18, Fluoride-18 For Bone Imaging

5) By Rubidium-82 (Rb-82): Rb-82 For PET (Positron Emission Tomography) Imaging, Rb-82 For Cardiac Imaging

6) By Iodine-131 (I-131): I-131 Sodium Iodide, I-131 For Thyroid Cancer Treatment, I-131 For Hyperthyroidism Treatment

7) By Lutetium-177 (Lu-177): Lu-177-DOTATATE, Lu-177 For Prostate Cancer Treatment

8) By Radium-223 (Ra-223): Ra-223 Dichloride (Xofigo), Alpharadin For Bone Metastasis Treatment

9) By Alpharadin (Radium-223 Alpha Emitters): Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)

10) By Other Types: Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)

Nuclear Medicine Radioisotopes Market Transformation Trends: What Innovations Are Driving Change?

Leading companies within the nuclear medicine radioisotopes market are concentrating on creating novel solutions, such as next-generation theranostic radiopharmaceuticals, aimed at improving precision imaging and targeted treatment. These advanced radioactive agents are engineered to both detect and precisely address diseases by accurately targeting particular cells within the body. For instance, in November 2025, the University of California, a US-based research university, established a fully autonomous Department of Nuclear Medicine & Theranostics, separating nuclear medicine from its previous inclusion under a wider radiology department. The purpose of this new department is to expedite the incorporation of sophisticated imaging techniques and targeted radiopharmaceutical treatments, while also reinforcing research, educational, and clinical initiatives to further precision medicine and foster advancements in theranostic therapies.

Nuclear Medicine Radioisotopes Market Competitive Analysis Of Leading Industry Participants

Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., Eczacibasi-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation

View The Full Nuclear Medicine Radioisotopes Market Report:

https://thebusinessresearchcompany.com/report/nuclear-medicine-radioisotopes-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Nuclear Medicine Radioisotopes Market Regional Analysis: Which Geography Leads On Revenue?

North America was the largest region in the nuclear medicine radioisotopes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Nuclear Medicine Radioisotopes Market Forecast: What Market Value Is Expected By 2030?

The nuclear medicine radioisotopes market has experienced significant expansion in recent years, with its value projected to rise from $8.85 billion in 2025 to $9.58 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.2%. This historical growth has been driven by the extensive application of technetium-99m in diagnostic imaging, a surge in nuclear cardiology procedures, a growing incidence of cancer and thyroid disorders, broader establishment of hospital-based nuclear medicine departments, and favorable outcomes from early clinical trials involving radioisotope-based therapies.

The nuclear medicine radioisotopes market is anticipated to experience robust expansion over the coming years, with its value projected to reach $12.75 billion by 2030, reflecting a compound annual growth rate (CAGR) of 7.4%. This forecasted growth is driven by several key factors, including the increasing need for personalized cancer treatments, the expanding application of lutetium-177 and actinium-225 therapies, and the enhancement of PET imaging infrastructure. Additional contributors are the rising investments in cyclotron and reactor facilities, along with the growing acceptance of nuclear medicine in emerging economies. Notable trends shaping the forecast period encompass the greater adoption of theranostics in oncology, the surge in demand for PET and SPECT imaging procedures, and the amplified use of targeted alpha and beta emitters. Furthermore, the widening role of nuclear medicine in cardiology and neurology, together with an intensified focus on local radioisotope production, is also shaping the market’s evolution.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16132&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Nuclear Medicine Radioisotopes Market Growth Drivers And Industry Catalysts

The escalating prevalence of cardiovascular diseases is anticipated to boost the expansion of the nuclear medicine radioisotope market in the coming period. These diseases encompass disorders affecting the heart and blood vessels. Their increasing frequency stems from sedentary behaviors, unhealthy eating patterns, higher obesity rates, and aging demographics. Radioisotopes used in nuclear medicine are crucial for diagnosing, assessing, and managing heart conditions, offering detailed information on cardiac function, blood flow, and tissue health—vital for precise diagnosis and effective treatment strategies. As of January 2024, the American Heart Association, a nonprofit organization based in the United States, reported that the age-adjusted mortality rate from cardiovascular disease rose to 233.3 per 100,000 individuals, reflecting a 4.0% increase from 224.4 per 100,000 in 2023. Consequently, the growing incidence of cardiovascular conditions is fueling demand for nuclear medicine radioisotopes.

Nuclear Medicine Radioisotopes Market Segment Analysis And Revenue Opportunities

The nuclear medicine radioisotopes market covered in this report is segmented –

1) By Type: Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Iodine (I-123), Fluorine-18, Rubidium-82 (Rb-82), Iodine-131 (I-131), Lutetium-177 (Lu-177), Radium-223 (Ra-223) And Alpharadin, Other Types

2) By Application: Oncology, Cardiology, Thyroid, Neurology, Other Applications

3) By End-User: Hospitals, Diagnostic Centers, Specialty Clinics, Education And Research Institutes, Other End-Users

Subsegments:

1) By Technetium-99m (Tc-99m): Sodium Pertechnetate Tc-99m, Tc-99m MDP (Methylene Diphosphonate), Tc-99m HMPAO (Hexamethylpropyleneamine oxime)

2) By Thallium-201 (Tl-201): Thallous Chloride Tl-201, Thallium-201 for Cardiac Imaging

3) By Iodine-123 (I-123): Iodine-123 Sodium Iodide, Iodine-123 Ioflupane (DaTscan)

4) By Fluorine-18: FDG (Fluorodeoxyglucose) F-18, Fluoride-18 For Bone Imaging

5) By Rubidium-82 (Rb-82): Rb-82 For PET (Positron Emission Tomography) Imaging, Rb-82 For Cardiac Imaging

6) By Iodine-131 (I-131): I-131 Sodium Iodide, I-131 For Thyroid Cancer Treatment, I-131 For Hyperthyroidism Treatment

7) By Lutetium-177 (Lu-177): Lu-177-DOTATATE, Lu-177 For Prostate Cancer Treatment

8) By Radium-223 (Ra-223): Ra-223 Dichloride (Xofigo), Alpharadin For Bone Metastasis Treatment

9) By Alpharadin (Radium-223 Alpha Emitters): Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)

10) By Other Types: Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)

Nuclear Medicine Radioisotopes Market Trends Influencing Long-Term Demand

Leading market players in the nuclear medicine radioisotopes sector are concentrating on creating novel approaches, such as next-generation theranostic radiopharmaceuticals, to improve targeted therapy and precise imaging. These advanced radioactive agents are designed to both identify and treat diseases by accurately targeting specific body cells. For example, in November 2025, the University of California, a US-based research institution, established a fully independent Department of Nuclear Medicine & Theranostics, separating it from the broader radiology department. This initiative aims to fast-track the integration of sophisticated imaging with targeted radiopharmaceutical therapies. Additionally, it enhances research, education, and clinical efforts to push precision medicine forward and spur innovations in theranostic treatments.

Nuclear Medicine Radioisotopes Market Leading Players Shaping Industry Direction

Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., Eczacibasi-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation

Access The Complete Nuclear Medicine Radioisotopes Market Report:

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-radioisotopes-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Nuclear Medicine Radioisotopes Market Regional Analysis And Leading Geography

North America was the largest region in the nuclear medicine radioisotopes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Are The Forecasted Market Size Figures For The Nuclear Medicine Radioisotopes Market In 2026 And 2030?

The nuclear medicine radioisotopes market has seen significant expansion in recent years. Its valuation is predicted to increase from $8.85 billion in 2025 to $9.58 billion in 2026, advancing at a compound annual growth rate (CAGR) of 8.2%. The historical growth of this market can be linked to the widespread application of technetium-99m in diagnostic imaging, the rising embrace of nuclear cardiology procedures, the growing occurrence of cancer and thyroid conditions, the enlargement of hospital-based nuclear medicine departments, and the initial successful outcomes of radioisotope-based therapies.

The nuclear medicine radioisotopes market is poised for significant expansion in the upcoming years. Its valuation is projected to reach $12.75 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.4%. This anticipated growth is driven by factors such as an increasing demand for personalized cancer treatment, the expanding use of lutetium-177 and actinium-225 therapies, the development of PET imaging infrastructure, rising investments in cyclotron and reactor facilities, and the greater adoption of nuclear medicine in emerging economies. Noteworthy trends for the forecast period include the increasing integration of theranostics in oncology care, a heightened demand for PET and SPECT imaging procedures, the expanded application of targeted alpha and beta emitters, the diversification of nuclear medicine into cardiology and neurology, and a stronger emphasis on domestic radioisotope production.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16132&type=smp

Which Growth Factors Are Strengthening The Nuclear Medicine Radioisotopes Market Landscape?

The escalating incidence of cardiovascular diseases is anticipated to fuel the expansion of the nuclear medicine radioisotope market moving forward. Cardiovascular diseases are a collection of conditions that affect the heart and blood vessels. The rise in cardiovascular disease cases stems from sedentary lifestyles, poor dietary habits, increasing rates of obesity, and aging populations. Nuclear medicine radioisotopes are invaluable for diagnosing, evaluating, and managing cardiovascular diseases by offering detailed insights into cardiac function, perfusion, and tissue viability, which are essential for accurate diagnosis and effective treatment planning. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, up 4.0% from 224.4 per 100,000 in 2023. Therefore, the increasing number of cardiovascular disease cases is propelling the growth of the nuclear medicine radioisotope market.

What Are The Core Segment Classifications In The Nuclear Medicine Radioisotopes Market?

The nuclear medicine radioisotopes market covered in this report is segmented –

1) By Type: Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Iodine (I-123), Fluorine-18, Rubidium-82 (Rb-82), Iodine-131 (I-131), Lutetium-177 (Lu-177), Radium-223 (Ra-223) And Alpharadin, Other Types

2) By Application: Oncology, Cardiology, Thyroid, Neurology, Other Applications

3) By End-User: Hospitals, Diagnostic Centers, Specialty Clinics, Education And Research Institutes, Other End-Users

Subsegments:

1) By Technetium-99m (Tc-99m): Sodium Pertechnetate Tc-99m, Tc-99m MDP (Methylene Diphosphonate), Tc-99m HMPAO (Hexamethylpropyleneamine oxime)

2) By Thallium-201 (Tl-201): Thallous Chloride Tl-201, Thallium-201 for Cardiac Imaging

3) By Iodine-123 (I-123): Iodine-123 Sodium Iodide, Iodine-123 Ioflupane (DaTscan)

4) By Fluorine-18: FDG (Fluorodeoxyglucose) F-18, Fluoride-18 For Bone Imaging

5) By Rubidium-82 (Rb-82): Rb-82 For PET (Positron Emission Tomography) Imaging, Rb-82 For Cardiac Imaging

6) By Iodine-131 (I-131): I-131 Sodium Iodide, I-131 For Thyroid Cancer Treatment, I-131 For Hyperthyroidism Treatment

7) By Lutetium-177 (Lu-177): Lu-177-DOTATATE, Lu-177 For Prostate Cancer Treatment

8) By Radium-223 (Ra-223): Ra-223 Dichloride (Xofigo), Alpharadin For Bone Metastasis Treatment

9) By Alpharadin (Radium-223 Alpha Emitters): Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)

10) By Other Types: Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)

Which Trends Are Influencing The Expansion Of The Nuclear Medicine Radioisotopes Market?

Leading companies in the nuclear medicine radioisotopes market are dedicated to developing inventive solutions, such as next-generation theranostic radiopharmaceuticals, to improve the precision of imaging and the effectiveness of targeted treatments. These advanced theranostic radiopharmaceuticals are sophisticated radioactive agents crafted to both identify and accurately treat diseases by specifically targeting particular cells within the body with great precision. For example, in November 2025, the University of California, a US-based research university, initiated a fully independent Department of Nuclear Medicine & Theranostics, moving nuclear medicine from its previous position under a broader radiology department. This new department intends to accelerate the integration of advanced imaging and targeted radiopharmaceutical therapies. It also aims to bolster research, education, and clinical programs to further precision medicine and stimulate innovations in theranostic treatments.

Who Are The Businesses Driving Activity In The Nuclear Medicine Radioisotopes Market?

Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., Eczacibasi-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation

Access The Complete Nuclear Medicine Radioisotopes Market Report:

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-radioisotopes-global-market-report

Which Region Stands As The Largest Contributor To The Nuclear Medicine Radioisotopes Market?

North America was the largest region in the nuclear medicine radioisotopes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Nuclear Medicine Radioisotopes Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=16132&type=smp

Browse Through More Reports Similar to the Global Nuclear Medicine Radioisotopes Market 2026, By The Business Research Company

Nuclear Medicine Radioisotopes Market Report 2026

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-radioisotopes-global-market-report

Diagnostic Radioisotopes Market Report 2026

https://www.thebusinessresearchcompany.com/report/diagnostic-radioisotopes-global-market-report

Nuclear Medicine Market Report 2026

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Nuclear Medicine Radioisotopes Market Between 2026 And 2030?

The nuclear medicine radioisotopes market has seen substantial expansion in recent years. It is anticipated to expand from $8.85 billion in 2025 to $9.58 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.2%. This historical growth can be linked to the extensive utilization of technetium-99m in diagnostic imaging, the increasing adoption of nuclear cardiology procedures, the rising occurrence of cancer and thyroid disorders, the growth of hospital-based nuclear medicine departments, and the early favorable outcomes of radioisotope-based therapies.

The nuclear medicine radioisotopes market size is anticipated to experience significant growth in the upcoming years. It is projected to expand to $12.75 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.4%. This expected growth can be attributed to factors such as the increasing demand for personalized cancer treatment, the rising application of lutetium-177 and actinium-225 therapies, the expansion of PET imaging infrastructure, growing investments in cyclotron and reactor facilities, and the increasing adoption of nuclear medicine in emerging economies. Major trends foreseen for this period include the rising acceptance of theranostics in oncology care, a growing demand for PET and SPECT imaging procedures, increased use of targeted alpha and beta emitters, the expansion of nuclear medicine into cardiology and neurology, and an enhanced focus on domestic radioisotope production.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16132&type=smp

What Key Drivers Are Fueling The Growth Of The Nuclear Medicine Radioisotopes Market?

An anticipated expansion in the nuclear medicine radioisotope market is linked to the increasing incidence of cardiovascular diseases. Cardiovascular diseases encompass various conditions impacting the heart and circulatory system. The growing prevalence of cardiovascular diseases stems from factors such as inactive lifestyles, unhealthy eating patterns, escalating obesity rates, and an aging demographic. Nuclear medicine radioisotopes play a crucial role in the diagnosis, assessment, and management of cardiovascular diseases, offering comprehensive data on cardiac performance, blood flow, and tissue health, all vital for precise diagnosis and successful therapeutic strategies. For example, in January 2024, the American Heart Association, a US-based non-profit organization, reported an increase in the age-adjusted death rate from cardiovascular disease to 233.3 per 100,000 in 2024, representing a 4.0% rise from 224.4 per 100,000 in 2023. Consequently, the escalating occurrences of cardiovascular diseases are fueling the expansion of the nuclear medicine radioisotope market.

What Are The Different Segment Types In The Nuclear Medicine Radioisotopes Market Segment Breakdown?

The nuclear medicine radioisotopes market covered in this report is segmented –

1) By Type: Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Iodine (I-123), Fluorine-18, Rubidium-82 (Rb-82), Iodine-131 (I-131), Lutetium-177 (Lu-177), Radium-223 (Ra-223) And Alpharadin, Other Types

2) By Application: Oncology, Cardiology, Thyroid, Neurology, Other Applications

3) By End-User: Hospitals, Diagnostic Centers, Specialty Clinics, Education And Research Institutes, Other End-Users

Subsegments:

1) By Technetium-99m (Tc-99m): Sodium Pertechnetate Tc-99m, Tc-99m MDP (Methylene Diphosphonate), Tc-99m HMPAO (Hexamethylpropyleneamine oxime)

2) By Thallium-201 (Tl-201): Thallous Chloride Tl-201, Thallium-201 for Cardiac Imaging

3) By Iodine-123 (I-123): Iodine-123 Sodium Iodide, Iodine-123 Ioflupane (DaTscan)

4) By Fluorine-18: FDG (Fluorodeoxyglucose) F-18, Fluoride-18 For Bone Imaging

5) By Rubidium-82 (Rb-82): Rb-82 For PET (Positron Emission Tomography) Imaging, Rb-82 For Cardiac Imaging

6) By Iodine-131 (I-131): I-131 Sodium Iodide, I-131 For Thyroid Cancer Treatment, I-131 For Hyperthyroidism Treatment

7) By Lutetium-177 (Lu-177): Lu-177-DOTATATE, Lu-177 For Prostate Cancer Treatment

8) By Radium-223 (Ra-223): Ra-223 Dichloride (Xofigo), Alpharadin For Bone Metastasis Treatment

9) By Alpharadin (Radium-223 Alpha Emitters): Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)

10) By Other Types: Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)

What Trends Are Affecting The Growth Of The Nuclear Medicine Radioisotopes Market?

Leading companies in the nuclear medicine radioisotopes market are concentrating on developing innovative solutions, such as next-generation theranostic radiopharmaceuticals, to improve the precision of imaging and the effectiveness of targeted treatment. These advanced theranostic radiopharmaceuticals are sophisticated radioactive agents designed to both detect and accurately treat diseases by specifically targeting cells within the body with high precision. For example, in November 2025, the University of California, a US-based research university, established an entirely independent Department of Nuclear Medicine & Theranostics, rather than maintaining nuclear medicine within a broader radiology framework. This new department aims to accelerate the integration of advanced imaging and targeted radiopharmaceutical therapies. It also works to strengthen research, education, and clinical programs to advance precision medicine and foster innovations in theranostic treatments.

Who Are The Well-Known Companies In The Nuclear Medicine Radioisotopes Market?

Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., Eczacibasi-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation

Get The Full Nuclear Medicine Radioisotopes Market Report:

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-radioisotopes-global-market-report

Where Is The Nuclear Medicine Radioisotopes Market Primarily Concentrated By Region?

North America was the largest region in the nuclear medicine radioisotopes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Nuclear Medicine Radioisotopes Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-radioisotopes-global-market-report

Browse Through More Reports Similar to the Global Nuclear Medicine Radioisotopes Market 2026, By The Business Research Company

Nuclear Medicine Radioisotopes Market Report 2026

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-radioisotopes-global-market-report

Diagnostic Radioisotopes Market Report 2026

https://www.thebusinessresearchcompany.com/report/diagnostic-radioisotopes-global-market-report

Nuclear Medicine Market Report 2026

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Nuclear Medicine Radioisotopes Market Projected To Become By 2030 Based On Its 2026 Valuation?

The market for nuclear medicine radioisotopes has demonstrated robust expansion recently. This market is projected to expand from $8.85 billion in 2025 to $9.58 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.2%. Historically, this expansion has been driven by the extensive application of technetium-99m in diagnostic imaging, increasing uptake of nuclear cardiology procedures, the rising incidence of cancer and thyroid conditions, the enlargement of nuclear medicine departments within hospitals, and the initial successful clinical outcomes of radioisotope-based treatments.

The nuclear medicine radioisotopes market is projected to experience substantial growth in the upcoming years, reaching $12.75 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.4%. This expansion during the forecast period is fueled by several factors, including an increased demand for personalized cancer treatments, a surge in the application of lutetium-177 and actinium-225 therapies, the broadening of PET imaging infrastructure, increased capital expenditure in cyclotron and reactor facilities, and the growing acceptance of nuclear medicine in developing nations. Key trends anticipated for this period encompass the increasing integration of theranostics within oncology, a heightened need for PET and SPECT imaging, expanded utilization of targeted alpha and beta emitters, the spread of nuclear medicine applications into cardiology and neurology, and an intensified emphasis on localized radioisotope manufacturing.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16132&type=smp

What Drivers Are Shaping The Future Growth Of The Nuclear Medicine Radioisotopes Market?

The increasing prevalence of cardiovascular diseases is anticipated to propel the expansion of the nuclear medicine radioisotope market in the future. Cardiovascular diseases encompass various ailments that impact the heart and blood vessels. The rise in these cases is attributed to sedentary lifestyles, poor dietary habits, escalating rates of obesity, and aging populations. Nuclear medicine radioisotopes prove invaluable in the diagnosis, evaluation, and management of cardiovascular diseases by offering detailed insights into cardiac function, perfusion, and tissue viability, which are crucial for accurate diagnosis and effective treatment planning. For instance, in January 2024, as per the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease climbed to 233.3 per 100,000 in 2024, marking a 4.0% increase from 224.4 per 100,000 in 2023. Therefore, the growing instances of cardiovascular diseases are driving the growth of the nuclear medicine radioisotope market.

What Segment Groups Are Identified Within The Nuclear Medicine Radioisotopes Market?

The nuclear medicine radioisotopes market covered in this report is segmented –

1) By Type: Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Iodine (I-123), Fluorine-18, Rubidium-82 (Rb-82), Iodine-131 (I-131), Lutetium-177 (Lu-177), Radium-223 (Ra-223) And Alpharadin, Other Types

2) By Application: Oncology, Cardiology, Thyroid, Neurology, Other Applications

3) By End-User: Hospitals, Diagnostic Centers, Specialty Clinics, Education And Research Institutes, Other End-Users

Subsegments:

1) By Technetium-99m (Tc-99m): Sodium Pertechnetate Tc-99m, Tc-99m MDP (Methylene Diphosphonate), Tc-99m HMPAO (Hexamethylpropyleneamine oxime)

2) By Thallium-201 (Tl-201): Thallous Chloride Tl-201, Thallium-201 for Cardiac Imaging

3) By Iodine-123 (I-123): Iodine-123 Sodium Iodide, Iodine-123 Ioflupane (DaTscan)

4) By Fluorine-18: FDG (Fluorodeoxyglucose) F-18, Fluoride-18 For Bone Imaging

5) By Rubidium-82 (Rb-82): Rb-82 For PET (Positron Emission Tomography) Imaging, Rb-82 For Cardiac Imaging

6) By Iodine-131 (I-131): I-131 Sodium Iodide, I-131 For Thyroid Cancer Treatment, I-131 For Hyperthyroidism Treatment

7) By Lutetium-177 (Lu-177): Lu-177-DOTATATE, Lu-177 For Prostate Cancer Treatment

8) By Radium-223 (Ra-223): Ra-223 Dichloride (Xofigo), Alpharadin For Bone Metastasis Treatment

9) By Alpharadin (Radium-223 Alpha Emitters): Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)

10) By Other Types: Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)

What Trends Are Advancing Progress In The Nuclear Medicine Radioisotopes Market?

Major companies in the nuclear medicine radioisotopes market are concentrating on developing innovative solutions, such as next-generation theranostic radiopharmaceuticals, to improve precision imaging and targeted treatment. These advanced theranostic radiopharmaceuticals are sophisticated radioactive agents designed to both detect and accurately treat diseases by specifically targeting cells in the body with high precision. For instance, in November 2025, the University of California, a US-based research university, inaugurated a completely independent Department of Nuclear Medicine & Theranostics, rather than keeping nuclear medicine under the broader radiology scope. This new department aims to accelerate the integration of advanced imaging and targeted radiopharmaceutical therapies. It also strengthens research, education, and clinical programs to advance precision medicine and foster innovations in theranostic treatments.

Which Companies Hold Significant Positions In The Nuclear Medicine Radioisotopes Market?

Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., Eczacibasi-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation

Read the full nuclear medicine radioisotopes market report here:

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-radioisotopes-global-market-report

Which Geographic Regions Are Influencing Demand In The Nuclear Medicine Radioisotopes Market?

North America was the largest region in the nuclear medicine radioisotopes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Nuclear Medicine Radioisotopes Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16132&type=smp

Browse Through More Reports Similar to the Global Nuclear Medicine Radioisotopes Market 2026, By The Business Research Company

Nuclear Medicine Radioisotopes Market Report 2026

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-radioisotopes-global-market-report

Diagnostic Radioisotopes Market Report 2026

https://www.thebusinessresearchcompany.com/report/diagnostic-radioisotopes-global-market-report

Nuclear Medicine Market Report 2026

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the nuclear medicine radioisotopes market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Nuclear Medicine Radioisotopes Market in 2030?

The nuclear medicine radioisotopes market size has experienced significant growth in recent years. It is projected to expand from $8.85 billion in 2025 to $9.58 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.2%. This historical growth can be attributed to the widespread utilization of technetium-99m in diagnostic imaging, increasing adoption of nuclear cardiology procedures, a rising prevalence of cancer and thyroid disorders, the expansion of hospital-based nuclear medicine departments, and the early clinical success of radioisotope-based therapies.

The nuclear medicine radioisotopes market is set to experience robust expansion in the upcoming years, with its size projected to reach $12.75 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.4%. This anticipated growth during the forecast period can be attributed to factors such as the increasing demand for personalized cancer treatment, the expanding application of lutetium-177 and actinium-225 therapies, the development of PET imaging infrastructure, rising investments in cyclotron and reactor facilities, and the growing adoption of nuclear medicine in emerging economies. Key trends expected over this period include the rising integration of theranostics in oncology care, a growing demand for PET and SPECT imaging procedures, increased use of targeted alpha and beta emitters, the broadening scope of nuclear medicine in cardiology and neurology, and a strengthening focus on domestic radioisotope production.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16132&type=smp

What Drivers Are Influencing Production Trends In The Nuclear Medicine Radioisotopes Market?

An anticipated increase in cardiovascular disease incidence is projected to boost the expansion of the nuclear medicine radioisotope market moving ahead. These conditions encompass a range of ailments impacting the heart and its vascular system. The escalation in cardiovascular disease cases can be attributed to factors such as inactive lifestyles, unhealthy eating patterns, a surge in obesity rates, and an aging demographic. Nuclear medicine radioisotopes play a crucial role in the diagnosis, assessment, and management of cardiovascular conditions, offering precise data on heart function, blood flow, and tissue health, which are vital for accurate identification and successful treatment strategies. An illustrative example comes from January 2024, when the American Heart Association, a US-based non-profit, reported an increase in the age-adjusted death rate from cardiovascular disease, reaching 233.3 per 100,000 in 2024, a 4.0% rise from 224.4 per 100,000 in 2023. Consequently, the growing incidence of cardiovascular diseases is serving as a catalyst for the expansion of the nuclear medicine radioisotope market.

Which Segment Groups Are Influencing The Nuclear Medicine Radioisotopes Market?

The nuclear medicine radioisotopes market covered in this report is segmented –

1) By Type: Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Iodine (I-123), Fluorine-18, Rubidium-82 (Rb-82), Iodine-131 (I-131), Lutetium-177 (Lu-177), Radium-223 (Ra-223) And Alpharadin, Other Types

2) By Application: Oncology, Cardiology, Thyroid, Neurology, Other Applications

3) By End-User: Hospitals, Diagnostic Centers, Specialty Clinics, Education And Research Institutes, Other End-Users

Subsegments:

1) By Technetium-99m (Tc-99m): Sodium Pertechnetate Tc-99m, Tc-99m MDP (Methylene Diphosphonate), Tc-99m HMPAO (Hexamethylpropyleneamine oxime)

2) By Thallium-201 (Tl-201): Thallous Chloride Tl-201, Thallium-201 for Cardiac Imaging

3) By Iodine-123 (I-123): Iodine-123 Sodium Iodide, Iodine-123 Ioflupane (DaTscan)

4) By Fluorine-18: FDG (Fluorodeoxyglucose) F-18, Fluoride-18 For Bone Imaging

5) By Rubidium-82 (Rb-82): Rb-82 For PET (Positron Emission Tomography) Imaging, Rb-82 For Cardiac Imaging

6) By Iodine-131 (I-131): I-131 Sodium Iodide, I-131 For Thyroid Cancer Treatment, I-131 For Hyperthyroidism Treatment

7) By Lutetium-177 (Lu-177): Lu-177-DOTATATE, Lu-177 For Prostate Cancer Treatment

8) By Radium-223 (Ra-223): Ra-223 Dichloride (Xofigo), Alpharadin For Bone Metastasis Treatment

9) By Alpharadin (Radium-223 Alpha Emitters): Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)

10) By Other Types: Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)

What Upcoming Trends Are Likely To Define The Future Path Of The Nuclear Medicine Radioisotopes Market?

Leading entities within the nuclear medicine radioisotopes market are directing their efforts towards creating cutting-edge solutions, specifically next-generation theranostic radiopharmaceuticals, to improve the accuracy of imaging and the specificity of treatments. These next-generation theranostic radiopharmaceuticals are sophisticated radioactive compounds developed to both identify and accurately treat illnesses by precisely targeting particular cells within the body. An illustrative example occurred in November 2025, when the University of California, a US-based research institution, established a fully autonomous Department of Nuclear Medicine & Theranostics, opting to position nuclear medicine as a distinct entity rather than part of a larger radiology department. This newly formed department is intended to expedite the merger of advanced imaging techniques with targeted radiopharmaceutical therapies. Furthermore, it seeks to bolster research, educational, and clinical initiatives, thereby fostering progress in precision medicine and propelling advancements in theranostic solutions.

Who Are The Top-Performing Companies In The Nuclear Medicine Radioisotopes Market In Recent Years?

Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., Eczacibasi-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-radioisotopes-global-market-report

Which Region Currently Holds The Largest Share Of The Nuclear Medicine Radioisotopes Market?

North America was the largest region in the nuclear medicine radioisotopes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Nuclear Medicine Radioisotopes Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16132&type=smp

Browse Through More Reports Similar to the Global Nuclear Medicine Radioisotopes Market 2026, By The Business Research Company

Nuclear Medicine Radioisotopes Market Report 2026

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-radioisotopes-global-market-report

Diagnostic Radioisotopes Market Report 2026

https://www.thebusinessresearchcompany.com/report/diagnostic-radioisotopes-global-market-report

Nuclear Medicine Market Report 2026

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the wound care biologics market from 2025–2034 with trusted insights from The Business Research Company

What Are The Future Growth Projections For The Wound Care Biologics Market Size?

The nuclear medicine radioisotopes market has experienced substantial expansion over the past few years. It is projected to expand from $8.21 billion in 2024 to reach $8.85 billion in 2025, driven by a compound annual growth rate (CAGR) of 7.9%. Historically, this growth has been influenced by factors such as the discovery of radioactivity, the emergence of nuclear medicine, the development of therapeutic applications, ongoing clinical research, and increasing patient demand.

The nuclear medicine radioisotopes market size is anticipated to undergo significant expansion in the coming years, reaching “$11.96 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.8%. This projected growth throughout the forecast period is fueled by increasing healthcare spending, the expansion of healthcare infrastructure, a growing focus on environmental sustainability, various education campaigns and awareness programs, and the rise of medical tourism. Prominent trends expected in this period include the development of new radioisotopes, innovations in production and supply chains, the adoption of microfluidics and lab-on-a-chip technology, the integration of artificial intelligence in radiopharmaceutical development, and advancements in nanotechnology.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16132&type=smp

What Core Market Drivers Are Expanding The Wound Care Biologics Industry?

The increasing incidence of cardiovascular diseases is anticipated to accelerate the expansion of the nuclear medicine radioisotope market going forward. These conditions refer to a group of ailments impacting the heart and blood vessels. The escalation in cardiovascular disease cases stems from sedentary lifestyles, poor dietary habits, rising rates of obesity, and aging populations. Nuclear medicine radioisotopes are invaluable for diagnosing, evaluating, and managing cardiovascular diseases, offering detailed insights into cardiac function, perfusion, and tissue viability, which are essential for accurate diagnosis and effective treatment planning. For instance, in September 2024, data published by the British Heart Foundation, a UK-based cardiovascular research charity, indicated that in the UK, approximately 7.6 million people are affected by heart and circulatory diseases, with around 4 million males and 3.6 million females living with these conditions. These diseases are responsible for about 27% of all deaths in the UK, translating to over 170,000 deaths annually, or roughly 480 deaths each day, equating to one death every three minutes. Consequently, the rising cases of cardiovascular diseases are driving the growth of the nuclear medicine radioisotope market.

What Segment Insights Are Highlighted In The Wound Care Biologics Market Report?

The nuclear medicine radioisotopes market covered in this report is segmented –

1) By Type: Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Iodine (I-123), Fluorine-18, Rubidium-82 (Rb-82), Iodine-131 (I-131), Lutetium-177 (Lu-177), Radium-223 (Ra-223) And Alpharadin, Other Types

2) By Application: Oncology, Cardiology, Thyroid, Neurology, Other Applications

3) By End-User: Hospitals, Diagnostic Centers, Specialty Clinics, Education And Research Institutes, Other End-Users

Subsegments:

1) By Technetium-99m (Tc-99m): Sodium Pertechnetate Tc-99m, Tc-99m MDP (Methylene Diphosphonate), Tc-99m HMPAO (Hexamethylpropyleneamine oxime)

2) By Thallium-201 (Tl-201): Thallous Chloride Tl-201, Thallium-201 for Cardiac Imaging

3) By Iodine-123 (I-123): Iodine-123 Sodium Iodide, Iodine-123 Ioflupane (DaTscan)

4) By Fluorine-18: FDG (Fluorodeoxyglucose) F-18, Fluoride-18 For Bone Imaging

5) By Rubidium-82 (Rb-82): Rb-82 For PET (Positron Emission Tomography) Imaging, Rb-82 For Cardiac Imaging

6) By Iodine-131 (I-131): I-131 Sodium Iodide, I-131 For Thyroid Cancer Treatment, I-131 For Hyperthyroidism Treatment

7) By Lutetium-177 (Lu-177): Lu-177-DOTATATE, Lu-177 For Prostate Cancer Treatment

8) By Radium-223 (Ra-223): Ra-223 Dichloride (Xofigo)

9) By Alpharadin (Radium-223 Alpha Emitters): Alpharadin For Bone Metastasis Treatment

10) By Other Types: Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)

Which Notable Trends Are Transforming The Wound Care Biologics Market Outlook?

Major companies in the nuclear medicine radioisotopes market are concentrating on developing innovative products, such as the compact low-energy cyclotron, to improve radioisotope production and availability, ensuring more efficient and accessible diagnostic and therapeutic options. A compact, low-energy cyclotron is a small particle accelerator utilized to create radioisotopes for medical imaging and treatments within nuclear medicine. For instance, in January 2022, IBA, a Belgium-based provider of radiopharmaceutical production solutions, launched Cyclone Key, a new accelerator that enhances access to diagnostic solutions and facilitates the in-house production of radiopharmaceuticals. This innovative solution offers unique features like a compact and efficient design, fully automated operation, multiple isotope production capabilities, ease of installation and use, water cooling, self-shielding, and high performance, making it versatile and reliable.

Which Firms Are Driving Innovation Within The Wound Care Biologics Market?

Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., Eczacıbaşı-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-radioisotopes-global-market-report

What Regional Trends Are Shaping Growth In The Wound Care Biologics Market?

North America was the largest region in the nuclear medicine radioisotopes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=16132&type=smp

Browse Through More Reports Similar to the Global Wound Care Biologics Market 2025, By The Business Research Company

Nuclear Imaging Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nuclear-imaging-devices-and-equipment-global-market-report

Nuclear Electricity Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nuclear-electricity-global-market-report

Nuclear Power Reactor Decommissioning Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nuclear-power-reactor-decommissioning-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Present And Forecasted Size Of The Nuclear Medicine Radioisotopes Market?

The market size of nuclear medicine radioisotopes has experienced considerable growth in recent years. Its size is projected to increase from $8.21 billion in 2024 to $8.85 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.9%. The factors driving the growth in the past were associated with the discovery of radioactivity, the emergence of nuclear medicine, therapeutic applications, clinical research, and increased patient demand.

Significant surges are anticipated in the nuclear medicine radioisotopes market size over the coming years, with projections pegging it at $11.96 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.8%. This forecasted growth can be ascribed to factors such as enhanced healthcare expenditure, advancement of healthcare facilities, heightened awareness towards environmental sustainability, educational drives and awareness initiatives, and growth in medical tourism. Furthermore, emerging trends during this forecast period encompass the creation of new radioisotopes, innovations within production and supply chain, microfluidics and lab-on-a-chip technology, incorporation of artificial intelligence in radiopharmaceutical development, and nanotechnology.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16132&type=smp

Which Market Dynamics Are Playing A Critical Role In The Growth Of The Nuclear Medicine Radioisotopes Market?

The growth of the nuclear medicine radioisotope market is predicted to be fueled by the increasing instances of cardiovascular diseases. A term denoting a cluster of diseases affecting the heart and blood vessels, cardiovascular diseases have seen a surge due to factors such as a sedentary lifestyle, poor eating habits, increased obesity rates, and aging demographics. Radioisotopes in nuclear medicine play a critical role in diagnosing and managing cardiovascular diseases by providing detailed information about cardiac function, perfusion, and tissue viability, which are crucial for precise diagnosis and effective treatment planning. For instance, stats published by the British Heart Foundation, a cardiovascular research charity based in the UK, revealed that 7.6 million people, comprised of 4 million men and 3.6 million women, battled heart and circulatory diseases in the UK, as of September 2024. These conditions were the culprit behind around 27% of all UK deaths, equivalent to over 170,000 deaths every year, or about 480 daily deaths. This translates to one person dying every three minutes. Hence, the growth of the nuclear medicine radioisotope market can be associated with the rising instances of cardiovascular diseases.

What Are The Main Segment Classifications In The Nuclear Medicine Radioisotopes Market?

The nuclear medicine radioisotopes market covered in this report is segmented –

1) By Type: Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Iodine (I-123), Fluorine-18, Rubidium-82 (Rb-82), Iodine-131 (I-131), Lutetium-177 (Lu-177), Radium-223 (Ra-223) And Alpharadin, Other Types

2) By Application: Oncology, Cardiology, Thyroid, Neurology, Other Applications

3) By End-User: Hospitals, Diagnostic Centers, Specialty Clinics, Education And Research Institutes, Other End-Users

Subsegments:

1) By Technetium-99m (Tc-99m): Sodium Pertechnetate Tc-99m, Tc-99m MDP (Methylene Diphosphonate), Tc-99m HMPAO (Hexamethylpropyleneamine oxime)

2) By Thallium-201 (Tl-201): Thallous Chloride Tl-201, Thallium-201 for Cardiac Imaging

3) By Iodine-123 (I-123): Iodine-123 Sodium Iodide, Iodine-123 Ioflupane (DaTscan)

4) By Fluorine-18: FDG (Fluorodeoxyglucose) F-18, Fluoride-18 For Bone Imaging

5) By Rubidium-82 (Rb-82): Rb-82 For PET (Positron Emission Tomography) Imaging, Rb-82 For Cardiac Imaging

6) By Iodine-131 (I-131): I-131 Sodium Iodide, I-131 For Thyroid Cancer Treatment, I-131 For Hyperthyroidism Treatment

7) By Lutetium-177 (Lu-177): Lu-177-DOTATATE, Lu-177 For Prostate Cancer Treatment

8) By Radium-223 (Ra-223): Ra-223 Dichloride (Xofigo)

9) By Alpharadin (Radium-223 Alpha Emitters): Alpharadin For Bone Metastasis Treatment

10) By Other Types: Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)

How Are Industry Trends Steering The Expansion Of The Nuclear Medicine Radioisotopes Market?

The focus of leading businesses in the nuclear medicine radioisotopes market is on the creation of innovative products like the compact low-energy cyclotron for enhancing radioisotope production and availability, thereby ensuring more effective, readily available diagnostic and therapeutic solutions. A compact low-energy cyclone, a mini particle accelerator, is employed for the creation of radioisotopes useful in medical imaging and nuclear medicine treatments. To exemplify, IBA, a radiopharmaceutical production solutions provider hailing from Belgium, introduced Cyclone Key, a new accelerator, in January 2022 to broaden the reach of diagnostic alternatives and facilitate in-house radiopharmaceutical production. The innovative solution boasts unique attributes such as a compact, efficient structure, fully programmed operation, the ability to produce multiple isotopes, installation and operation convenience, water cooling, self-protection, and high performance, bringing about versatility and dependability.

Which Firms Are Driving Innovation Within The Nuclear Medicine Radioisotopes Market?

Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., Eczacibasi-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-radioisotopes-global-market-report

What Are The Emerging Regional Trends Driving The Nuclear Medicine Radioisotopes Market?

North America was the largest region in the nuclear medicine radioisotopes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=16132&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Much Is the Global Wound Care Biologics Market Valued at Present and by 2029?

In recent years, the nuclear medicine radioisotopes market has seen substantial growth. It is projected to increase from $8.21 billion in 2024 to $8.85 billion in 2025, representing a compound annual growth rate (CAGR) of 7.9%. The growth during the historical period can be ascribed to the discovery of radioactivity, the development of nuclear medicine, therapeutic uses, clinical studies, and demands from patients.

It is anticipated that the nuclear medicine radioisotopes market will undergo substantial expansion in the coming years, and it’s projected to reach an estimated worth of $11.96 billion in 2029, expanding at a compound annual growth rate (CAGR) of 7.8%. The predicted surge over the forecast period is linked to factors such as rising expenditure in healthcare, improvements in healthcare facilities, increasing consciousness about environmental sustainability, educational drives and awareness initiatives, and the rise of medical tourism. The forecast period also sees trends like the invention of new radioisotopes, breakthroughs in production and supply chain, microfluidics and lab-on-a-chip technology, the use of artificial intelligence in developing radiopharmaceuticals and the application of nanotechnology.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16132&type=smp

#What Drivers Are Influencing Growth In The Wound Care Biologics Market?

The escalating incidence of diabetes is anticipated to boost the rise of the wound care biologics market in the imminent future. Diabetes is a long-term metabolic disorder signified by increased levels of blood glucose (or blood sugar), which over time inflicts devastating damage to the heart, blood vessels, eyes, kidneys, and nerves. Biological wound care thwarts excessive water loss, thermal loss, protein and electrolyte loss, plus contamination. Furthermore, they facilitate autolytic debridement and create a granular wound layer. The elevated incidence of diabetes is a key factor propelling the growth of the wound care biologics market. For instance, as per the National Health Service (NHS), a UK-based government agency, the count of individuals under 40 affected, surged from 173,166 in 2022 to 216,440 in 2023 in June 2024. This marked escalation delineates a worrying pattern in this age demographic. The statistics underscore a fast acceleration in diabetes prevalence amongst the younger cohorts. Hence, the rampant incidence of diabetes is fuelling the wound care biologics market.

The nuclear medicine radioisotopes market covered in this report is segmented –

1) By Type: Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Iodine (I-123), Fluorine-18, Rubidium-82 (Rb-82), Iodine-131 (I-131), Lutetium-177 (Lu-177), Radium-223 (Ra-223) And Alpharadin, Other Types

2) By Application: Oncology, Cardiology, Thyroid, Neurology, Other Applications

3) By End-User: Hospitals, Diagnostic Centers, Specialty Clinics, Education And Research Institutes, Other End-Users

Subsegments:

1) By Technetium-99m (Tc-99m): Sodium Pertechnetate Tc-99m, Tc-99m MDP (Methylene Diphosphonate), Tc-99m HMPAO (Hexamethylpropyleneamine oxime)

2) By Thallium-201 (Tl-201): Thallous Chloride Tl-201, Thallium-201 for Cardiac Imaging

3) By Iodine-123 (I-123): Iodine-123 Sodium Iodide, Iodine-123 Ioflupane (DaTscan)

4) By Fluorine-18: FDG (Fluorodeoxyglucose) F-18, Fluoride-18 For Bone Imaging

5) By Rubidium-82 (Rb-82): Rb-82 For PET (Positron Emission Tomography) Imaging, Rb-82 For Cardiac Imaging

6) By Iodine-131 (I-131): I-131 Sodium Iodide, I-131 For Thyroid Cancer Treatment, I-131 For Hyperthyroidism Treatment

7) By Lutetium-177 (Lu-177): Lu-177-DOTATATE, Lu-177 For Prostate Cancer Treatment

8) By Radium-223 (Ra-223): Ra-223 Dichloride (Xofigo)

9) By Alpharadin (Radium-223 Alpha Emitters): Alpharadin For Bone Metastasis Treatment

10) By Other Types: Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)

What Trends Are Currently Influencing Growth In The Wound Care Biologics Market?

Leading businesses in the nuclear medicine radioisotopes market are honing their focus on the creation of innovative products like the compact low-energy cyclotron. This technology is aimed at enhancing the production and accessibility of radioisotopes, thereby ensuring that diagnostic and therapeutic options are more efficient and readily available. A compact low-energy cyclotron, essentially a mini particle accelerator, is employed in the creation of radioisotopes for medical imaging and treatments within the realm of nuclear medicine. As an exemplification, IBA, a Belgium-based company supplying solutions for radiopharmaceutical production, announced the launch of the Cyclone Key in January of 2022. This new accelerator aims to expand access to diagnostic solutions and enable in-house production of radiopharmaceuticals. This forward-thinking solution brings unique features to the table, including a compact and efficient design, complete automation, multiple isotope production abilities, water cooling, self-shielding, and high performance. This renders it versatile and trustworthy.

Which Companies Play A Key Role In The Development Of The Wound Care Biologics Market?

Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., Eczacıbaşı-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-radioisotopes-global-market-report

What Are The Key Regional Developments Shaping The Wound Care Biologics Market?

North America was the largest region in the nuclear medicine radioisotopes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=16132&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model